Mercado de modelos de xenoenxerto derivado de doentes do Médio Oriente e África (PDX) – Tendências do setor e previsão para 2030

Análise e tamanho do mercado de modelos de xenoenxerto derivado de doentes no Médio Oriente e África (PDX)

De acordo com a American Cancer Society, houve 1.735.350 novos casos de cancro diagnosticados nos Estados Unidos em 2018. Além disso, o Instituto Nacional do Cancro está a expandir o seu repositório de modelos de investigação do cancro em 2018 para incluir mais modelos de investigação. Bibliotecas PDX de grande escala estão a ser construídas no Médio Oriente, em África e nos Estados Unidos. O Instituto Nacional do Cancro dos Estados Unidos anunciou planos para fazer a transição do seu sistema de rastreio de medicamentos anticancerígenos da "Linha Celular Tumoral Humana NCI-60" para um novo sistema. Em comparação com os modelos de xenoenxerto derivados de linhagens celulares, espera-se que os modelos PDX tenham uma previsibilidade superior da eficácia do tratamento, preservando a heterogeneidade do tumor.

A Data Bridge Market Research analisa que o mercado de modelos de xenoenxerto derivado de doentes (PDX), que foi de 36.424,39 mil dólares em 2022, deverá atingir os 87.014,42 mil dólares até 2030, com um CAGR de 11,5 % durante o período de previsão de 2023 a 2030. Além de os insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research também incluem análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar .

Âmbito e segmentação do mercado de modelos de xenoenxerto derivado de pacientes do Médio Oriente e África (PDX)  

Definição de mercado

Os modelos PDX são considerados uma ferramenta eficaz na investigação biomédica e ensaios pré-clínicos porque ambas as espécies apresentam semelhanças e estes modelos são capazes de transportar as características do tumor e estudar o tumor e a sua heterogeneidade. Auxiliam na avaliação da taxa de crescimento do tumor, do ciclo de vida e da taxa de crescimento sob diversas condições. Ajudam também a distinguir entre cancro adulto e pediátrico. A utilização de modelos PDX na investigação básica do cancro e no desenvolvimento de tapetes permite a adoção de novas terapias, terapias específicas para os doentes e medicina personalizada.

Dinâmica do mercado de modelos de xenoenxerto derivado de doentes do Médio Oriente e África (PDX)

Motoristas

• Aumento da procura de modelos PDX para estudos de farmacologia e biomarcadores

O xenoenxerto tumoral e os modelos singénicos foram tradicionalmente utilizados para investigação em farmacologia oncológica, biomarcadores e farmacocinética/farmacodinâmica. O valor dos modelos PDX em operações normais de investigação aumentou à medida que a disponibilidade e o custo dos modelos PDX fornecidos por instituições académicas e empresas de investigação contratadas aumentaram. Uma revisão superficial dos programas de descoberta do cancro publicados nos últimos três anos revela a utilização de modelos PDX em várias fases da descoberta pré-clínica e da investigação translacional. No entanto, a indústria do modelo PDX está a incorporar cada vez mais a leitura do modelo PDX como um componente crítico do pacote de dados necessário para uso interno e submissão regulamentar. A utilização de modelos PDX no desenvolvimento de fármacos pode ser rastreada há várias décadas.

• Crescente prevalência de doenças crónicas, aumentando a procura de medicamentos personalizados

The development of medicines for chronic diseases such as cancer has received a lot of attention. Cancer is now a major burden on healthcare systems worldwide. According to Worldwide cancer data released in 2020, approximately 18 million cancer cases and 10 million cancer deaths were recorded in 2020. In vitro and in vivo techniques are being developed to address the rising incidence of cancer and provide effective therapies to patients. Cancer is one of the leading causes of death worldwide. The disease has spread rapidly and is expected to spread significantly during the forecast period.

Each year, approximately 400 000 children are diagnosed with cancer. The most common cancers differ by country. As a result of the rising global prevalence of cancer, the market is being driven by an increase in the rate of diagnosis and demand for personalized medication.

Opportunities

• Growing adoption of humanized PDX models

Despite the fact that xenografts develop well in immunodeficient models, these models are primarily used to create PDX models. These models are insufficient for investigating stroma-tumour interactions, which are primarily responsible for tumour development and progression in patients. Humanized PDX models help with these challenges and are gaining popularity in the industry. To generate humanized xenograft models, immunodeficient mice (such as NOD SCID mice) are being reconstructed with bone marrow or peripheral blood cells and patient tumour implants. These models are ideal for studying the role of xenogeneic immune cells in overall anti-tumor immunity. They also help with the development of immunotherapy medications that target the immune system's effector arm.

Restraints/Challenges

• Unaffordable personalized PDX models

To develop individualized PDX models, a specimen of the patient's tumour is implanted and grown in a variety of immunocompromised models. It is then extracted, fragmented, and re-implanted in a larger group of models that have been treated with various medications and pharmacological combinations. Given the costs of developing and maintaining these models and the use of expensive medications in these models, PDX trials can cost thousands of dollars, even for a single patient. Using PDX models in government-funded fundamental research, on the other hand, could be prohibitively expensive. These are the primary factors limiting the adoption of PDX models.

This patient derived xenograft (PDX) models market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the patient derived xenograft (PDX) models market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Middle East and Africa Patient Derived Xenograft (PDX) Models Market

Covid-19 had a negative impact on the Middle East and Africa patient-derived xenograft (PDX) models market due to the decline in productivity in life science organizations during the pandemic. Reduced pharma R&D deals in therapeutic areas, disruption of clinical trials, and country-specific lockdowns all had an effect on the market. Oncology, ID/anti-infectives, cardiovascular disease, and respiratory disease trials were the most impacted. The market will resume growth as the impact of COVID-19 is expected to weaken in the post-pandemic scenario.

Recent developments

• In December 2020, Collagen Matrix, Inc., a global leader in collagen-based, regenerative, xenograft-derived medical devices, and Linden Capital Partners ("Linden") announced the acquisition of Sunstar's Degradable Solutions division. It included the GUIDOR branded line of resorbable synthetic medical implants. The investment aims to broaden the range of technologies available to customers.
• In April 2020, Crown Bioscience Inc. acquired unique models from Leading Academic Medical Centres, and the company signed agreements with Dana-Farber Cancer Institute and the University of Washington. This aids the company's product expansion and assists the oncology drug development community.

Middle East and Africa Patient Derived Xenograft (PDX) Models Market Scope

The patient derived xenograft (PDX) models market is segmented on the basis of type, tumour type, application, technique and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Mice Models
• Rat Models

Tumor Type

• Gastrointestinal Tumor Models
• Lung Tumor Models
• Haematological Tumor Models
• Gynecological Tumor Models
• Respiratory Tumor Models
• Urological Tumor Models
• Others

Application

• Preclinical Drug Development
• Precision Medicine
• Co-Clinical Trials
• Basic Cancer Research
• Biomarker Analysis
• Oncology Research

Technique

• Heterotopic Implantation
• Orthotropic Implantation

End User

• Academic and Research Organizations
• Contract Research Organizations
• Pharmaceutical and Biotechnological Companies
• Others

Patient Derived Xenograft (PDX) Models Market Regional Analysis/Insights

The patient derived xenograft (PDX) models market is analyzed and market size insights and trends are provided by country, type, tumour type, application, technique and end user as referenced above.

The countries covered in the patient derived xenograft (PDX) models market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

Saudi Africa is dominating the Middle East and Africa market with the rise in adoption of PDX models in preclinical research and also increasing R&D activities in the pharmaceutical industries.  

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The patient derived xenograft (PDX) models market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for patient derived xenograft (PDX) models market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the patient derived xenograft (PDX) models market. The data is available for historic period 2011-2021.

Competitive Landscape and Patient Derived Xenograft (PDX) Models Market Share Analysis

The patient derived xenograft (PDX) models market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to patient derived xenograft (PDX) models market.

Some of the major players operating in the patient derived xenograft (PDX) models market are:

• Crown Bioscience Inc. (U.S.)
• THE JACKSON LABORATORY (U.S.)
• Champions Oncology, Inc. (U.S.)
• Charles River Laboratories (U.S.)
• Wuxi AppTec (China)
• Oncodesign (Canada)
• Aragen Bioscience (India)
• Biocytogen (U.S.)
• Bioduro (EUA)
• Animodelo Criativo (EUA)
• (EUA)
• EPO Berlin-Buch GmbH (Alemanha)
• EUROPDX. (Bélgica)
• Explora BioLabs (EUA)
• Hera BioLabs (EUA)
• Horizon Discovery Ltd. (Reino Unido)
• Serviços Pharmatest (Finlândia)
• Urospehere SAS (Chipre)
• Xentech (França)
• Xenópata (França)

Metodologia de Investigação: Mercado de Modelos de Xenoenxerto Derivado de Doentes (PDX) no Médio Oriente e África

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou deixe a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Além disso, os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise da quota de mercado da empresa, padrões de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de pesquisa, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (Factbook) ou pode ajudá-lo na criação de apresentações a partir dos conjuntos de dados disponíveis no relatório.

SKU-54824